Last reviewed · How we verify
Nocardiosis — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Azo Gantanol | SULFAMETHOXAZOLE | Pfizer | Sulfonamide Antimicrobial [EPC] | 1973-01-01 | ||
| Azo Gantrisin | sulfafurazole | Alra | Sulfonamide Antimicrobial | Endothelin-1 receptor | 1971-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Alra · 1 drug in Nocardiosis
- Pfizer · 1 drug in Nocardiosis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Nocardiosis:
- Nocardiosis treatment updates — RSS
- Nocardiosis treatment updates — Atom
- Nocardiosis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Nocardiosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/nocardiosis. Accessed 2026-06-10.
Related
- Nocardiosis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing